Parnax Lab Ltd. () - Stock Overview & Analysis

Search your stocks

Profile

parnax-labParnax Lab Ltd.

₹133-2.46%

Market Cap

₹147.36 Cr

Stock P/E

105.63

ROCE

13.61%

ROE

14.39%

Book Value

₹62.32

You might have missed

No Recent News

No recent news available for this stock.

Shareholding

Holdings

Distribution

Promoter

Public

Others

Financials

YoY Net Sales

EPS Growth

Operating Margin

From Last Concall

No Concall Summary

Conference call summary is not available for this stock.

Peers Summary

Sector Leader

In the Pharmaceuticals & Drugs sector, Parnax Lab Ltd. shows underwhelming performance with negative revenue growth and a high PE ratio compared to its peers. However, peers like Cipla Ltd. and Dr. Reddy's Laboratories Ltd. demonstrate strong profitability and growth metrics, positioning them as sector leaders. Parnax Lab should focus on improving growth and profitability to align with industry standards.

Key Points

• Parnax Lab has negative revenue growth and high PE, indicating underperformance.
• Cipla Ltd. and Dr. Reddy's Laboratories Ltd. lead in profitability metrics and growth.
• Divi's Laboratories, while highly valued, shows weak growth, making it a potential value trap.

Top Performers

Cipla Ltd.

Strong revenue growth (13.28% YoY) and the lowest PE ratio (23.73) among peers.

Dr. Reddy's Laboratories Ltd.

Excellent profitability with a ROE of 21.76% and a low PE of 15.50.

Mankind Pharma Ltd.

Highest revenue growth (18.12% YoY) and solid ROE (23.15%).